UK switches over to Merck, Sanofi HPV vaccine

LONDON Thu Nov 24, 2011 11:20am EST

LONDON Nov 24 (Reuters) - Britain will switch to using the HPV vaccine Gardasil, supplied by Sanofi Pasteur MSD, from September next year, instead of GlaxoSmithKline's rival product Cervarix, the government said on Thursday.

The decision follows a competitive tendering exercise that was won by the joint venture operation of Merck & Co and Sanofi.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.